Cimerli Success Drives Strong H1 At Formycon

Company Anticipates Highest Revenue In Its History Over Subsequent Quarters

 
• By Chloe Kent

Formycon delivered a strong H1, as its Lucentis biosimilar made significant strides in the US market. The company now anticipates the highest revenue in its history for 2023.

Piece of torn paper reading 'Coming soon!'
Formycon expects the best results in its history to come soon • Source: Shutterstock

More from Earnings

More from Business